This record was last updated May 2, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The project examines the hypothesis that monoclonal allergen-neutralizing antibodies can be recombinantly produced from B lymphocytes isolated from pollen allergic patients. Patient samples suitable for antibody cloning are selected based on seroprofiling for the respective allergens. The study aims at isolating lymphocytes from patients with potential allergen-neutralizing IgG in serum and to clone antibodies from antibody gene sequences obtained from B cells of those patients.
Protocol Amendment History
5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2018-10-31; most recent amendment 2025-04-29.